EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Clinical efficacy and safety of bipolar water as a therapeutic approach for oral candidiasis: a randomized controlled trial

Peiru Zhou, Jiakun Fang, Yanhong Meng, Jiangli Zheng, Furong Yang, Mingming Xu, Xu Zhang, Hong Hua

Clinical Oral Investigations · 2025

DOI: 10.1007/s00784-025-06500-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Oral Investigations, 2025. Verfasst von Peiru Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Medicine, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Cent…. Hauptthemen laut MEDLINE: Candidiasis, Oral, Mouthwashes, Antifungal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: The Program of New Clinical Techniques of Peking University School and Hospital of Stomatology, National Key Research and Development Program, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Oral candidiasis (OC) is a fungal infection caused primarily by Candida albicans. Treatments are associated with side-effects and toxicity. Bipolar water (BW), a novel functional water with antimicrobial, biofilm-disrupting, and wound-healing properties, offers a promising alternative therapy.This clinical trial aimed at evaluating the efficacy and safety of BW in OC treatment. METHODS: This randomized controlled trial enrolled 72 participants diagnosed with OC. Participants were randomized into four groups: BW mouthwash at two concentrations (HOCl at 40-55 mg/L, group 1; HOCl at 120 mg/L ± 20 mg/L, group 2), BW mouthwash (HOCl at 40-55 mg/L combined with nystatin tablets, group 3), and control group (CG; nystatin tablets and sodium-bicarbonate mouthwash). Efficacy was evaluated by clinical efficacy, mycological efficacy, and comprehensive efficacy (defined as a combination of clinical and mycological responses), and safety was assessed by adverse event (AE) monitoring. P-values were considered significant if < 0.05. The treatment schedule was as follows: BW mouthwash (groups 1, 2, and 3) was used five times a day, nystatin was taken three times a day (group 3), and sodium-bicarbonate mouthwash was used three times a day in the control group. RESULTS: At 14 days, groups 1 and 2 demonstrated percent clinical response of 76.5% and 64.7%, respectively, which was comparable with that in the CG (64.7%). Values for mycological response were 47.1% and 37.5%, with clearance of 23.5% and 18.8%, respectively. The CG achieved a significantly higher percent clearance (76.5%). With respect to comprehensive efficacy, there was no significant difference between the three groups (88.2%, 82.4%, and 88.2% for groups 1, 2, and 3, respectively), but percent cure was higher in the CG (52.9%) than in group 1 (17.6%) and group 2 (11.8%). At 28 days, group 3 achieved the highest values for clinical response (87.5%) and cure (68.8%), marginally exceeding that for the CG (76.5% and 58.8%, respectively). There was no significant difference between the two groups with respect to clinical efficacy, mycologic efficacy, and comprehensive efficacy. BW was well-tolerated, with only mild AEs reported (e.g., oral irritation), which did not merit treatment discontinuation. CONCLUSIONS: BW mouthwash, as a standalone or adjunctive therapy with nystatin tablets, is a safe and efficacious treatment for OC, significantly alleviating clinical symptoms and improving the chance of cure. CLINICAL RELEVANCE: The findings of this study provide valuable evidence on the clinical benefits of BW in treating OC, and may contribute to the development of new therapeutic options for this common (but challenging) condition. CLINICAL TRIAL REGISTRATION: The trial was registered at the Chinese Clinical Trial Registry (ChiCTR) under the registration number ChiCTR2400087579.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Candidiasis, OralMouthwashesAntifungal AgentsHumansMaleFemaleTreatment OutcomeNystatinAdultMiddle AgedSodium Bicarbonate

Stichwörter der Autor:innen

AntifungalBipolar waterClinical efficacyMycological efficacyOral candidiasisSafety

Substanzen

MouthwashesAntifungal AgentsNystatinSodium Bicarbonate

Autor:innen und Institutionen

  • Department of Oral Medicine, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Bi…
  • Office of Operations Management, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Ora…
  • Department of Clinical Laboratory, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of O…
  • Department of Geriatric Dentistry, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of O…
  • Center of Digital Dentistry, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Bi…

Förderung

  • The Program of New Clinical Techniques of Peking University School and Hospital of Stomatology
  • National Key Research and Development Program
  • National Key Research and Development Program of China
  • Young Elite Scientist Sponsorship Program by BAST

Zitieren

APA

Zhou, P., Fang, J., Meng, Y., Zheng, J., Yang, F., Xu, M., Zhang, X., & Hua, H. (2025). Clinical efficacy and safety of bipolar water as a therapeutic approach for oral candidiasis: a randomized controlled trial. Clinical Oral Investigations. https://doi.org/10.1007/s00784-025-06500-4

Vancouver

Zhou P, Fang J, Meng Y, Zheng J, Yang F, Xu M, et al. Clinical efficacy and safety of bipolar water as a therapeutic approach for oral candidiasis: a randomized controlled trial. Clinical Oral Investigations. 2025. doi:10.1007/s00784-025-06500-4

BibTeX
@article{Zhou2025,
  author = {Zhou, Peiru and Fang, Jiakun and Meng, Yanhong and Zheng, Jiangli and Yang, Furong and Xu, Mingming and Zhang, Xu and Hua, Hong},
  title = {Clinical efficacy and safety of bipolar water as a therapeutic approach for oral candidiasis: a randomized controlled trial},
  journal = {Clinical Oral Investigations},
  year = {2025},
  doi = {10.1007/s00784-025-06500-4}
}
Kostenlos starten →